Evidence supporting the use of: Alpha-Lipoic Acid
For the health condition: Diabetic Retinopathy

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Alpha-lipoic acid (ALA) has been studied for its potential benefits in diabetic retinopathy primarily due to its antioxidant properties. Diabetic retinopathy is a microvascular complication of diabetes, largely driven by oxidative stress and inflammation in the retina. ALA is known to be a potent antioxidant that can regenerate other antioxidants and reduce oxidative stress in various tissues, including the eye. Several animal studies and in vitro experiments have demonstrated that ALA can decrease markers of oxidative damage in retinal cells exposed to hyperglycemia. Some small human clinical trials and open-label studies have suggested that ALA supplementation may improve visual function or slow the progression of early diabetic retinopathy, but these studies are limited by small sample sizes, short durations, and methodological weaknesses. Meta-analyses and systematic reviews typically conclude that while there is a theoretical rationale and some preliminary evidence for ALA's use, robust clinical trial data are lacking, and its efficacy in preventing or treating diabetic retinopathy in humans has not been conclusively demonstrated. Thus, the use of ALA for diabetic retinopathy is supported by some scientific rationale and preclinical evidence, but clinical evidence is weak and not definitive.

More about Alpha-Lipoic Acid
More about Diabetic Retinopathy

Products containing Alpha-Lipoic Acid

We currently have no products on Vitabase that contain this ingredient.